NCT04825834已完成不适用
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,992
- 试验地点
- 56
- 主要终点
- Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.
研究概览
简要总结
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
详细描述
Subjects will be enrolled into the DELFI-L101 study after informed consent and eligibility is confirmed. At enrollment, subjects will have blood specimens collected (~40 mL) and 12 months post-enrollment their medical records will be reviewed.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All Participants:
- •Ability to understand and provide written informed consent
- •Age ≥ 50 years
- •Current or Former Smoker
- •≥ 20 pack-years (pack years = number of packs per day X number of years smoked)
- •Inclusion Group 1: High Risk Patients that meet criteria 5 and 6 below:
- •Prior thoracic imaging with computed tomography (CT) within 12 months of enrollment (CT imaging for lung cancer screening for participants meeting inclusion criteria 6a and 6b; or CT imaging for lung cancer screening or diagnostic CT for participants meeting inclusion criteria 6c)
- •OR Planned thoracic imaging (CT) as part of standard of care within 6 weeks of enrollment (CT imaging for lung cancer screening for participants meeting inclusion criteria 6a and 6b; or CT imaging for lung cancer screening or diagnostic CT for participants meeting inclusion criteria 6c)
- •Meet one of the criteria below:
- •No suspected or confirmed lung cancer diagnosis OR
- •Suspected of lung cancer OR
- •Confirmed, untreated lung cancer
- •Inclusion Group 2: High Risk Patients that meet the following criteria:
- •Pathologic confirmed, invasive non-lung cancer diagnosis, originating from the esophagus (upper), colon or rectum, pancreas, stomach (including lower esophagus), head and neck, skin (excluding cutaneous basal cell and squamous cell carcinoma) kidney, or liver, with no prior systemic therapy, definitive therapy, radiation, or surgical resection.
- •OR Clinically confirmed invasive non-lung cancer diagnosis originating from the pancreas, kidney, or liver, based on imaging and clinical judgment with planned treatment and no prior systemic therapy, definitive therapy, radiation, or surgical resection.
- •OR Clinically (based on imaging and clinical judgment) or pathologically confirmed non-invasive or invasive bladder cancer with planned treatment and no prior systemic therapy, definitive therapy, radiation or surgical resection.
排除标准
- •All Participants:
- •Prior systemic therapy, definitive therapy, radiation, or surgical resection for cancer within one year prior to enrollment (with the exception of organ biopsies or surgery for non-melanoma skin cancer)
- •Any history of hematologic malignancies or myelodysplasia
- •Any history of organ tissue transplantation
- •Any history of blood product transfusion
- •Current pregnancy
- •Any condition that in the opinion of the Investigator should preclude the participant's participation in the study
- •Prior systemic therapy, definitive therapy, radiation, or surgical resection for the enrollment cancer diagnosis (with the exception of organ biopsies or surgery for non-melanoma skin cancer are not exclusionary)
- •Enrollment in any DELFI sponsored study
结局指标
主要结局
Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.
时间窗: Approximately 12 months
次要结局
- Accuracy (sensitivity and specificity) in clinical subgroups of interest(Approximately 12 months)
- Analytical performance (e.g. repeatability/reproducibility)(Approximately 12 months)
- Accuracy of multi-cancer detection measured by sensitivity, specificity, and the AUC of the ROC and tissue of origin (TOO) accuracy(Approximately 12 months)
- Prevalence-based measures, including positive predictive value (PPV), negative predictive value (NPV), and number needed to screen (NNS)(Approximately 12 months)
- Accuracy of tumor of origin (confusion matrix of predicted versus actual cancer type)(Approximately 12 months)
- Adverse events (AEs) associated with the blood specimen collection(Point in time of blood specimen collection (1day) at enrollment)
- Expected distribution of the DELFI score in the intended use population and clinical subgroups of interest(Approximately 12 months)
- Association of genomic features with clinical subgroups of interest(Approximately 12 months)
研究者
研究点 (56)
Loading locations...
相似试验
招募中
不适用
Biomarkers for Risk Stratification in Lung CancerNodule Solitary PulmonaryNon-small Cell Lung CancerNCT03774758University of California, San Francisco590
招募中
不适用
Rural Illinois Lung Cancer Screening InitiativeLung CancerNCT06084078Southern Illinois University10,000
招募中
不适用
Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)Lung CancerNCT04817046Peking University People's Hospital467
招募中
不适用
The Early Diagnosis of Pulmonary Nodule Based on Multi-dimension MessagesPulmonary Nodule, SolitaryNode LungNCT04005677Wuhan Union Hospital, China500
招募中
不适用
Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOsSpreading of TumorCirculating Tumor CellLung CancerNCT05187767University of Roma La Sapienza80